Nasusaf (Azelastine Hydrochloride, Fluticasone Propionate)

Azelastine Hydrochloride and Fluticasone Propionate, the active ingredients in Nasusaf, are an antihistamine and corticosteroid presented as a nasal spray for nasal use. It treats seasonal and perennial allergic rhinitis and allergic nasal congestion in adults and children.

GNH USA supplies Nasusaf as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nasusaf is indicated for allergic rhinitis and related nasal congestion, acting on inflammatory and histamine pathways. - Seasonal allergic rhinitis: reduces sneezing, itching, rhinorrhea and nasal blockage during pollen seasons. - Perennial allergic rhinitis: controls year‑round symptoms caused by indoor allergens. - Allergic nasal congestion: alleviates swelling and mucus production to improve nasal airflow.

Nasusaf may cause local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation - Headache - Bitter or unpleasant taste - Epistaxis (nosebleed) - Cough - Throat irritation

Serious or Rare Side Effects: - Nasal septal perforation - Severe allergic reaction (anaphylaxis) - Vision changes or cataract formation - Profound or persistent nosebleeds - Adrenal suppression with prolonged high‑dose use

Before prescribing Nasusaf, consider the following precautions. - Assess diagnosis: confirm allergic rhinitis before initiating therapy. - Hypersensitivity: avoid in patients with known allergy to azelastine, fluticasone or formulation excipients. - Local irritation: monitor for persistent nasal bleeding or severe irritation. - Recent nasal surgery or trauma: use with caution to prevent delayed healing. - Pregnancy and lactation: evaluate risk‑benefit and consult a healthcare professional. - Store at room temperature: keep in original container, protect from moisture and heat.

Nasusaf can interact with other medicines; review patient medication lists.

Major Interactions (Avoid): - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic fluticasone exposure. - Monoamine oxidase inhibitors (MAOIs): can potentiate antihistamine effects and increase risk of sedation.

Moderate Interactions (Monitor Closely):\n- Concurrent intranasal corticosteroids: additive systemic steroid effect. - Antifungal azoles (e.g., fluconazole): may modestly raise fluticasone levels. - Beta‑blockers: may mask early signs of anaphylaxis. - Other antihistamines: may increase sedation or anticholinergic burden.